Indefinite Delivery Contract 75D30122D12996
Award Date
12/31/21
Last Date to Order
2/28/23
Federal Agency
CDC Pittsburgh
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325411 - Medicinal and Botanical Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Centers for Disease Control and Prevention awarded a single-award indefinite delivery contract to Glaxosmithkline, LLC to procure adult influenza vaccines. The contract has a potential value of $13 million and a period of performance from December 2020 through February 2022. The original solicitation sought proposals for the purchase of influenza vaccines for individuals aged 19 years and older to support immunization programs under Section 317(j) of the Public Health Service Act. Offerors...
The Indefinite Delivery Contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh provides adult flu vaccines for the 2023-2024 period. Glaxosmithkline, LLC was awarded a multiple award contract with a potential value of $13.9 million to deliver flu vaccines through February 2028 under associated task orders or price lists. The solicitation aimed to procure adult flu vaccines to support the Centers for Disease Control and Prevention's...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a multiple award indefinite delivery contract to Seqirus USA Inc. for adult flu vaccines for 2023-2024. The potential value of the contract is $146,103,060. Orders may be placed through February 28, 2024. The contract aims to procure adult flu vaccines to support the CDC's efforts in disease prevention. As the leading public health agency in the United States, the CDC works to control and prevent...
The Centers for Disease Control and Prevention (CDC) awarded a single award Indefinite Delivery Contract to Glaxosmithkline, LLC, a pharmaceutical company, to procure pediatric influenza vaccines for the 2022-2023 season. The contract has a potential value of $168,590,000 and a period of performance from the date of award through February 28, 2023. The original solicitation sought between 100 doses and 50 million doses of pediatric influenza vaccine to be delivered to CDC distribution centers in...
This single-award Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Sanofi Pasteur Inc. to provide adult influenza vaccines for the 2022-2023 flu season. The contract has a ceiling value of $65,825,903.80 and a period of performance from the date of award on December 31, 2021 through February 28, 2023. The original solicitation sought proposals for IDIQ contracts to supply a minimum of 100 doses and a maximum of 20 million doses of...
The Centers for Disease Control and Prevention awarded Sanofi Pasteur Inc. a multiple-award indefinite delivery contract with a potential value of $67,076,901.90 to procure adult flu vaccines for 2023-2024. No set-aside was used for this award. Under the terms of the contract, the awardee will deliver flu vaccines to the CDC through the period ending February 28, 2024. The solicitation sought to procure adult flu vaccines in support of the CDC's efforts to prevent the spread of influenza. As the...
This indefinite delivery contract was awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to provide pediatric flu vaccines for the 2020-2021 season. The contract has a potential value of $140.25 million and was awarded to Glaxosmithkline, LLC on January 7, 2020, with an ordering period through February 28, 2021. The original solicitation sought proposals to supply between 60-80 million doses of pediatric flu vaccines for nationwide delivery....
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide adult influenza vaccines for the 2024-2025 season. The $13,916,000 multiple award IDC has a period of performance through February 28, 2025. The contract does not have any set-aside designations. Glaxosmithkline will likely provide the vaccines from its facilities in North Carolina to support the CDC's immunization programs...
This indefinite-delivery, indefinite-quantity (IDIQ) contract was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, to Glaxosmithkline, LLC, a pharmaceutical company, for the purchase of 12 standard adult vaccines. The $172.4 million contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and does not utilize any set-asides. The vaccines, which include influenza, hepatitis, pneumococcal, and...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $143,324,800 contract is for the procurement of adult influenza vaccines for the 2022-2023 flu season, with a period of performance from the award date of December 31, 2021 through February 28, 2023. The contract does not utilize any set-asides and was awarded...